Skip to main content


Advances in CAR-T Cell Therapies for Glioma

Thursday, June 13, 2024
11:00 AM - 12:00 PM ET

Complimentary Registration!  

This activity is provided by the Society for Neuro-Oncology.

Target Audience
Neuro-oncologists, medical oncologists, neurosurgeons, radiation oncologists, radiologists, neuropathologists, physicians/scientists, clinical and laboratory trainees, and allied health professionals.

Statement of Need/Program Overview
Chimeric Antigen Receptor (CAR) T-cell therapy is an innovative immunotherapy technique holding immense potential in oncology. This groundbreaking approach involves genetically modifying immune cells to target tumor-specific antigens, successfully treating some hematologic malignancies. High-grade gliomas, aggressive primary brain tumors with limited treatment options, present a significant challenge in oncology. However, recent reports have showcased promising early outcomes using CAR T-cell therapy for recurrent high-grade gliomas. 
This webinar aims to outline recent advances in CAR T-cell therapy for gliomas, discussing its implications and challenges in neuro-oncology. Additionally, it will explore future directions for research in this field.

Educational Objectives 
After participating in this CME activity, participants should be able to:
  • Discuss various approaches to CAR T-cell therapy
  • Review recent advances to CAR T-cell therapies for glioma
  • Identify challenges and barriers to using CAR T-cell therapy for gliomas and other CNS tumors
  • Steven Bagley - University of Pennsylvania
  • Bryan Choi - Mass General Research Institute
  • Michelle Monje - Stanford University
Program Agenda
To view the program, click here. 

Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation 
The Society for Neuro-Oncology designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit 
In order to receive credit for this activity, the participant must attend the meeting virtually and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant at the conclusion of the webinar from The Society for Neuro-Oncology with the subject line "Instructions to Receive Credit for Advances in CAR-T Cell Therapies for Glioma webinar" 

For technical assistance with claiming CME credit, please email [email protected].

Deadline to claim CE Credit will be Friday, July 12, 2024, at 11:59 pm ET.
Disclosure of Relevant Financial Relationships
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view disclosures, click here.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at [email protected]